Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
919
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus – Brief Report

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees

Francesca Dapportoa VisMederi srl, Siena, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7897-4452View further author information
ORCID Icon,
Margherita Leonardia VisMederi srl, Siena, ItalyView further author information
,
Claudia Maria Trombettab VisMederi Research srl, Siena, Italy;c Department of Molecular and Developmental Medicine, University of Siena, Siena, ItalyView further author information
,
Claudia Semplicia VisMederi srl, Siena, ItalyView further author information
,
Pietro Piua VisMederi srl, Siena, ItalyView further author information
,
Giulia Piccinia VisMederi srl, Siena, ItalyView further author information
,
Linda Benincasaa VisMederi srl, Siena, Italy;b VisMederi Research srl, Siena, ItalyView further author information
,
Serena Marchic Department of Molecular and Developmental Medicine, University of Siena, Siena, ItalyView further author information
,
Emanuele Andreanod Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, ItalyView further author information
,
Piero Lovreglioe Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari, Bari, ItalyView further author information
,
Nicola Buonvinof U.O.C. Penitentiary Medicine - Department of Territorial Care, Bari Local Health Authority, Bari, ItalyView further author information
,
Nicola Decarog Department of Veterinary Medicine, University of Bari, Valenzano, ItalyView further author information
,
Angela Stufanoe Interdisciplinary Department of Medicine, Section of Occupational Medicine, University of Bari, Bari, ItalyView further author information
,
Eleonora Lorussog Department of Veterinary Medicine, University of Bari, Valenzano, ItalyView further author information
,
Emilio Bombardierih Humanitas Gavazzeni, Bergamo, ItalyView further author information
,
Antonella Ruelloh Humanitas Gavazzeni, Bergamo, ItalyView further author information
,
Simonetta Vivianic Department of Molecular and Developmental Medicine, University of Siena, Siena, ItalyView further author information
,
Rino Rappuolid Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy;i Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, ItalyView further author information
,
Eleonora Molestia VisMederi srl, Siena, ItalyView further author information
,
Alessandro Manentia VisMederi srl, Siena, ItalyView further author information
&
Emanuele Montomolia VisMederi srl, Siena, Italy;b VisMederi Research srl, Siena, Italy;c Department of Molecular and Developmental Medicine, University of Siena, Siena, ItalyView further author information
 show all
Article: 2129196 | Received 28 Jul 2022, Accepted 22 Sep 2022, Published online: 21 Oct 2022

References

  • Errico JM, Adams LJ, Fremont DH. Antibody-mediated immunity to SARS-CoV-2 spike. Adv Immunol. 2022;154:1–5.
  • Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. J Phys Chem Lett. 2022;13(17):3840–49.
  • Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180(2):281–92. doi:10.1016/j.cell.2020.02.058.
  • Martinez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol. 2021;12:701501.
  • European Commission. Safe COVID-19 vaccines for Europeans; European Commission. 2022.
  • Elliott P, Eales O, Steyn N, Tang D, Bodinier B, Wang H, Elliott J, Whitaker M, Atchison C, Diggle PJ, et al. Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. Science. 2022;376(6600). doi:10.1126/science.abq4411.
  • Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, et al. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med (NY),3;1–17. 2022; S2666-6340(22):00321-X.
  • Marchi S, Viviani S, Remarque EJ, Ruello A, Bombardieri E, Bollati V, Milani GP, Manenti A, Lapini G, Rebuffat A, et al. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS One. 2021;16(7):e0253977. doi:10.1371/journal.pone.0253977.
  • Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938;27(3):493‐497. doi:10.1093/oxfordjournals.aje.a118408.
  • Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, Skov RL, Krause TG., Rasmussen M, Sieber RN, et al. Transmission of SARS-CoV-2. 1. Omicron VOC subvariants BA.1 and BA.2: 2: evidence from Danish households. MedRxiv. 2022.
  • Evans JP, Zeng C, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T, Lozanski G, Mallampalli R, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host Microb. 2022;30:1093–1102.
  • Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, Li M, Cui Y, Chen Y, Qiao R, et al. Antibody evasion of SARS-CoV-2 Omicron. BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30(8):1–7. doi:10.1016/j.chom.2022.05.001.
  • Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, Buonvino N, Stufano A, Lorusso E, Bombardieri E, et al. Antibody avidity and neutralizing response against SARS-CoV-2 Omicron variant after infection or vaccination. J Immunol Res. 2022;2022:4813199. doi:10.1155/2022/4813199.
  • Pratesi F, Caruso T, Testa D, Tarpanelli T, Gentili A, Gioè D, Migliorini P. Bnt162b2 mRNA SARS-CoV-2 vaccine elicits high avidity and neutralizing antibodies in healthcare workers. Vaccines (Basel). 2021;9(6). doi:10.3390/vaccines9060672.
  • Richterman A, Scott J, Cevik M. Covid-19 vaccines, immunity, and boosters. BMJ. 2021;375:n3105.
  • Rössler A, Netzl A, Knabl L, Schäfer H, Wilks SH, Bante D, Falkensammer B, Borena W, von Laer D, Smith D, et al. BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants [Preprint]. doi:10.1101/2022.05.10.22274906
  • Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785–90. doi:https://doi.org/10.1038/s41591-022-01911-2.
  • Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603–08. doi:10.1038/s41586-022-05053-w.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.